AMRN — Amarin Corporation plc

Amarin Corporation (AMRN) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total net revenue for Q2 2026 was $42.2 million, down from $72.7 million in Q2 2025, which included a $25 million upfront payment from Recordati.
• Product revenue decreased to $39.1 million from $46.6 million year-over-year.
• U.S. product revenue fell to $32.2 million from $36.5 million, impacted by pricing pressure, though branded prescriptions rose 14% year-over-year.
• European product revenue was $5.4 million, down from $6.6 million, but showed an 11% increase from Q1 2026 and a 140% increase from Q4 2025.
• Operating loss narrowed to $12 million from $16 million in Q2 2025.
• Cash and investments increased to $314.6 million, with positive cash flow of $7 million for the quarter, marking the third consecutive quarter of positive cash flow.

2. Strategic Updates and Business Highlights:

• Amarin has completed its restructuring, resulting in a significantly lower cost base and a more efficient operational structure.
• The company is executing a dual commercial strategy, focusing on U.S. operations while expanding internationally through partnerships, notably with Recordati, which has driven a 69% increase in in-market demand for VASCEPA in Europe.
• VASCEPA is now available in 22 countries, with VAZKEPA launched in 11 European countries, including a recent launch in Romania.
• Recordati has prioritized VAZKEPA in its cardiovascular portfolio, enhancing market access and adoption across Europe.

3. Forward Guidance and Outlook:

• Amarin expects stable U.S. volumes through the end of 2026 and anticipates continued positive cash flow for the full year.
• The company is optimistic about the growth potential in Europe and other international markets, with ongoing regulatory submissions and launches planned in countries like Singapore and South Korea for 2027.
• The management expressed confidence in the long-term partnerships and untapped potential globally.

4. Challenges and Points of Concern:

• Total net revenue decline reflects the absence of one-time payments and ongoing pricing pressure in the U.S. market due to generic competition.
• European revenue, while showing growth, remains lower than previous periods, indicating challenges in transitioning to a new commercial model.
• The company faces a lengthy reimbursement process in various European countries, which could slow down market penetration and revenue growth.

5. Notable Q&A Insights:

• Management acknowledged the complexity of the reimbursement landscape in Europe, with ongoing efforts to improve access in key markets like the U.K., Spain, and Italy.
• Questions regarding cost of goods sold (COGS) indicated that the recent increase is tied to regained exclusive pharmacy benefit manager relationships and is expected to stabilize as volume growth continues.
• The licensing revenue included $1.4 million from Recordati, indicating early signs of revenue growth from this partnership, with expectations for further ramp-up as market demand increases.

Overall, Amarin is navigating a transition phase with a focus on international growth and maintaining profitability in the U.S., while also addressing challenges related to pricing pressures and market access.